See more : Gamma Communications plc (GAMA.L) Income Statement Analysis – Financial Results
Complete financial analysis of Nicox S.A. (NICXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nicox S.A., a leading company in the Biotechnology industry within the Healthcare sector.
- Mydecine Innovations Group Inc. (MYCO.NE) Income Statement Analysis – Financial Results
- Vulcan International Corporation (VULC) Income Statement Analysis – Financial Results
- Suofeiya Home Collection Co., Ltd. (002572.SZ) Income Statement Analysis – Financial Results
- Vatti Corporation Limited (002035.SZ) Income Statement Analysis – Financial Results
- Electric Power Development Co., Ltd. (EDRWY) Income Statement Analysis – Financial Results
Nicox S.A. (NICXF)
About Nicox S.A.
Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. The company is also developing NCX 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and NCX 1728.It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was founded in 1996 and is headquartered in Valbonne, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 257.00K | 212.00K | 8.58M | 14.42M | 0.00 |
| Cost of Revenue | 11.76M | -23.35M | 1.35M | 1.52M | 0.00 |
| Gross Profit | -11.50M | 23.56M | 7.23M | 12.91M | 0.00 |
| Gross Profit Ratio | -4,475.88% | 11,111.79% | 84.27% | 89.49% | 0.00% |
| Research & Development | 0.00 | 17.99M | 17.91M | 12.73M | 17.75M |
| General & Administrative | 0.00 | 6.76M | 6.34M | 6.03M | 6.59M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 6.76M | 6.34M | 6.03M | 6.59M |
| Other Expenses | -11.50M | -2.24M | 68.00K | 112.00K | -42.67M |
| Operating Expenses | -11.50M | 16.51M | 25.40M | 19.92M | -18.33M |
| Cost & Expenses | 257.00K | -6.83M | 26.75M | 21.44M | -18.33M |
| Interest Income | 1.10M | 1.12M | 0.00 | 891.00K | 0.00 |
| Interest Expense | 1.63M | 1.63M | 2.02K | 2.21M | 0.00 |
| Depreciation & Amortization | 3.55M | 11.22M | 29.42M | 1.74M | 0.00 |
| EBITDA | -16.24M | -18.10M | -15.96M | -14.12M | -18.33M |
| EBITDA Ratio | -6,318.29% | -8,538.21% | 137.47% | -97.91% | 0.00% |
| Operating Income | -17.50M | -34.06M | -46.01M | -6.76M | -18.33M |
| Operating Income Ratio | -6,810.51% | -16,066.51% | -536.06% | -46.87% | 0.00% |
| Total Other Income/Expenses | -3.92M | 2.27M | -1.40M | -11.31M | -4.45M |
| Income Before Tax | -21.42M | -31.79M | -47.41M | -18.07M | 0.00 |
| Income Before Tax Ratio | -8,335.41% | -14,994.81% | -552.31% | -125.29% | 0.00% |
| Income Tax Expense | -478.00K | -504.00K | -3.64M | 28.00K | 0.00 |
| Net Income | -20.88M | -31.29M | -43.76M | -18.10M | 0.00 |
| Net Income Ratio | -8,124.90% | -14,757.08% | -509.86% | -125.48% | 0.00% |
| EPS | -0.42 | -0.62 | -1.17 | -0.54 | 0.00 |
| EPS Diluted | -0.42 | -0.62 | -1.17 | -0.54 | 0.00 |
| Weighted Avg Shares Out | 50.17M | 50.10M | 37.49M | 33.72M | 33.72M |
| Weighted Avg Shares Out (Dil) | 50.17M | 50.10M | 37.49M | 33.72M | 33.72M |
Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement
Nicox SA (NICXF) Upgraded to Buy: Here's What You Should Know
Source: https://incomestatements.info
Category: Stock Reports